SEC Filing Summary

Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, Inc., reported transactions on March 17, 2026. He acquired 417 shares of Common Stock at $15.44 per share and disposed of 417 shares of Common Stock at $25.65 per share. Additionally, he was granted a stock option for 417 shares of Common Stock, with a conversion or exercise price of $15.44. These transactions were made under a Rule 10b5-1 trading plan. The stock option vests over time, with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.